Biotech Values

[mcbio]

SLXP/(PGNX) @ JPM (1/11/12)

Starting just before the 22-minute mark of this presentation, as it relates to PGNX and Relistor, SLXP's CEO states that the current peak-year sales estimate for Relistor (she termed peak-year as being year 7) in its currently approved indication is about $50M. If they gain expanded approval in chronic patients, that peak estimate is $300-$350M. If SLXP/PGNX succeed in gaining approval for oral Relistor, that takes them to a "billion dollar opportunity."